GlassScriptPhysician profile
Alex Hertzman
NPI 1851316566
$52,232.03
in general payments reported to CMS, 2019-2025
18 companies · $847 in 2025
The $847 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $6,844 · 2021: $989 · 2022: $1,165 · 2023: $1,062 · 2024: $846 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $41,592.20 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $4,217.39 | 2019-2020 | |
| Amgen INC. | $1,459.54 | 2019-2025 | Evenity, Prolia, Enbrel |
| Abbvie INC. | $1,235.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,027.94 | 2019-2025 | |
| Janssen Biotech, INC. | $935.91 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $629.98 | 2019-2024 | Taltz |
| Pfizer INC. | $399.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $213.75 | 2019-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $152.28 | 2020-2024 | Strensiq |
| Ucb, INC. | $103.00 | 2019-2025 | Bimzelx |
| Celgene Corporation | $86.25 | 2019 | |
| Hikma Pharmaceuticals USA | $50.24 | 2019-2021 | |
| Alvogen INC | $40.26 | 2022-2024 | Teriparatide |
| Glaxosmithkline, LLC. | $38.65 | 2020-2025 | Benlysta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.01 | 2023 | Actemra |
| Avion Pharmaceuticals | $16.78 | 2020 | |
| Sandoz INC. | $14.65 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Hertzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.